Phase 3 study of ABT-494 versus placebo in rheumatoid arthritis with inadequate response to csDMARDs

Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing ABT-494 plus stable csDMARDs with Placebo plus stable csDMARDs (2 arms). Primary endpoints: Proportion of subjects achieving ACR20 response at Week 12 and Proportion of subjects achieving low disease activity at Week 12. Started Nov 2015; status: completed.